&nbsp;

Drugs Used:

abemaciclib,

anastrozole

Quick Link(s):

Regimen Monograph

Feb 2025

Regimen

CARFDEXALENA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

New Drug Funding Program

Carfilzomib (Triplet Therapy) - In Combination with Lenalidomide and Dexamethasone for Relapsed Multiple Myeloma

ODB - General Benefit

dexamethasone

ODB Limited Use

lenalidomide - For the treatment of patients with multiple myeloma, who are deemed to be lenalidomide sensitive, and/or have not experienced progression while on a lenalidomide-based regimen in the treatment or maintenance setting, according to clinical criteria

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2024

Regimen

DEXAIXAZLENA

Cancer Type:

Hematologic,

Multiple Myeloma

Intent: Palliative

Funding:

ODB - General Benefit

dexamethasone

Drugs Used:

ixazomib (Unfunded),

lenalidomide (Unfunded),

dexamethasone

Quick Link(s):

Regimen Monograph

May 2019

Regimen

GOSE

Cancer Type:

Genitourinary,

Prostate

Intent: Neoadjuvant, Adjuvant, Palliative

Funding:

ODB - General Benefit

goserelin

Drugs Used:

goserelin

Quick Link(s):

Regimen Monograph

Mar 2016

Regimen

LPRL

Cancer Type:

Genitourinary,

Prostate

Intent: Neoadjuvant, Adjuvant, Palliative

Funding:

ODB - General Benefit

leuprolide - long-acting formulation

Drugs Used:

leuprolide

Quick Link(s):

Regimen Monograph

May 2025

Regimen

CAPECISP

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

ODB - General Benefit

capecitabine

Drugs Used:

CISplatin,

capecitabine

Quick Link(s):

Regimen Monograph

May 2019

Regimen

FCM(PO)+R

Cancer Type:

Hematologic,

Lymphoma - Non-Hodgkin's Low Grade

Intent: Palliative

Funding:

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

ODB - General Benefit

cyclophosphamide - oral tablets

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Indolent Lymphoma

New Drug Funding Program

Rituximab (Biosimilar IV) and Rituximab SC in Combination with Chemotherapy - Indolent B-cell Lymphoma

Drugs Used:

riTUXimab,

mitoXANTRONE,

fludarabine (Unfunded),

cyclophosphamide,

riTUXimab (subcut)

Quick Link(s):

Regimen Monograph

Aug 2020

Regimen

CAPECISP+PEMB+TRAS; CAPE+PEMB+TRAS

Cancer Type:

Gastrointestinal,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

ODB - General Benefit

capecitabine

New Drug Funding Program

Pembrolizumab and Trastuzumab (Biosimilar) - First-line Treatment of Advanced HER2-Positive Gastric or Esophagogastric Junction Adenocarcinoma

Drugs Used:

Quick Link(s):

Regimen Monograph

Dec 2024

Regimen

CAPECISP+PEMB; CAPE+PEMB

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Pembrolizumab - First-line Treatment of Advanced HER2-negative Esophageal, Gastric, and Esophagogastric Junction Carcinoma

ODB - General Benefit

capecitabine

Drugs Used: